ONMD insider buying and SEC filings, explained
OneMedNet Corp · CIK 1849380
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$417K
Insiders who bought
4
Sold (not marked 10b5-1)
$321K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 7, 2026 | Other purchase | Thomas Kosasa (Director and 10% owner) bought 129,758 Common Stock at about $5.78 ($750K) in a private placement. Holdings up 7% to 1,983,573 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 13, 2026, 8:32 PM ET |
| Oct 9, 2026 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 45,126 Common Stock at about $5.54 ($250K) in a private placement. Holdings up 5% to 896,840 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 13, 2026, 8:32 PM ET |
| Sep 14–21, 2026 | Sale | Robert Lawrence Golden (CFO and Director) sold 8,500 shares between Sep 14 and Sep 21 at about $6.50 ($55K). Holdings down 9% to 91,291 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 9, 2026, 9:30 PM ET |
| Sep 22–24, 2026 | Sale | Aaron Green (CEO and Director) sold 6,667 shares between Sep 22 and Sep 24 at about $7.16 ($48K). Holdings down 3% to 247,971 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 9, 2026, 9:30 PM ET |
| Sep 10, 2026 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 142,857 Common Stock at about $0.6300 ($90K) in a private placement. Holdings up 2% to 8,923,267 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Jul 30, 2026 | Other purchase | Thomas Kosasa (Director and 10% owner) bought 1,449,275 Common Stock at about $0.6900 ($1.0M) in a private placement. Holdings up 8% to 18,538,150 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 7, 2026 |
| Jun 23, 2026 | Open-market purchase | Aaron Green (CEO and Director) bought 36,650 shares at $0.5700 ($21K) in an open-market purchase. Holdings up 2% to 1,896,375 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 24, 2026 |
| Jun 23, 2026 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 158,730 Common Stock at $0.6300 ($100K) in a private placement. Holdings up 2% to 8,780,410 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 24, 2026 |
| Jun 16, 2026 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 172,414 Common Stock at $0.5800 ($100K) in a private placement. Holdings up 2% to 8,621,680 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 12–15, 2026 | Purchase (code P) | Aaron Green (CEO and Director) bought 55,622 shares between Jun 12 and Jun 15 at about $0.5533 ($31K), reported as a purchase (code P). Holdings up 3% to 1,859,725 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 16, 2026 |
| Jun 12, 2026 | Other purchase | Thomas Kosasa (Director and 10% owner) bought 158,730 Common Stock at about $0.6300 ($100K) in a private placement. Holdings up 1% to 17,088,874 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 18, 2026 | Other purchase | Thomas Kosasa (Director and 10% owner) bought 268,817 Common Stock at about $0.9300 ($250K) in a private placement. Holdings up 2% to 16,930,144 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| Apr 1, 2026 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 903,614 Common Stock at about $0.8300 ($750K) in a private placement. Holdings up 12% to 8,229,837 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 24, 2026 |
| Feb 6–Apr 23, 2026 | Other purchase | Thomas Kosasa (Director and 10% owner) bought 876,136 Common Stock between Feb 6 and Apr 23 at about $0.8560 ($750K) in a private placement. Holdings up 6% to 16,661,327 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 24, 2026 |
| Oct 22–Nov 18, 2025 | Sale | Aaron Green (CEO and Director) sold 126,322 shares between Oct 22, 2025 and Nov 18, 2025 at about $1.73 ($218K). Holdings down 7% to 1,804,103 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 23, 2025 |
| May 9–Jun 20, 2025 | Other purchase | Jeffrey Yu (Chief Medical Officer and Director) bought 1,672,612 Common Stock in 2 share classes between May 9, 2025 and Jun 20, 2025 at about $0.4186 ($700K) in a private placement. Holdings of Common Stock up 33% to 6,737,410 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Aug 19–Sep 25, 2025 | Purchase (code P) | Jeffrey Yu (Chief Medical Officer and Director) bought 343,813 shares between Aug 19, 2025 and Sep 25, 2025 at about $0.7550 ($260K), reported as a purchase (code P). Holdings up 5% to 7,081,223 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Feb 1–Dec 18, 2024 | Purchase (code P) | Jeffrey Yu (Chief Medical Officer and Director) bought 9,540 shares between Feb 1, 2024 and Dec 18, 2024 at about $0.9359 ($9K), reported as a purchase (code P). Holdings up <1% to 2,763,195 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Jun 20–Aug 29, 2025 | Other purchase | Thomas Kosasa (Director) bought 1,771,871 Common Stock between Jun 20, 2025 and Aug 29, 2025 at about $0.5644 ($1.0M) in a private placement. Holdings up 13% to 15,734,191 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Apr 21–Sep 24, 2025 | Purchase (code P) | Thomas Kosasa (Director) bought 108,000 shares between Apr 21, 2025 and Sep 24, 2025 at about $0.4584 ($50K), reported as a purchase (code P). Holdings up 1% to 15,740,191 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Feb 16, 2024–Oct 15, 2025 | Purchase (code P) | Eric Casaburi (Director) bought 20,475 shares between Feb 16, 2024 and Oct 15, 2025 at about $1.92 ($39K), reported as a purchase (code P). Holdings up 46% to 65,475 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Dec 8, 2023–Jan 30, 2024 | Purchase (code P) | Jeffrey Yu (Chief Medical Officer and Director) bought 22,762 shares between Dec 8, 2023 and Jan 30, 2024 at about $0.7553 ($17K), reported as a purchase (code P). Holdings up 1% to 2,522,886 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Dec 7, 2023 | Purchase (code P) | Robert Lawrence Golden (CFO and Director) bought 300 shares at $1.71 ($513), reported as a purchase (code P). New position of 300 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ONMD in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.